Stock Analyses

Model-driven valuations for thousands of US-listed stocks, built from SEC EDGAR filings. Click any card to see the full analysis.

All sectors 6,479 Financial Services 1,900 Healthcare 1,116 Technology 1,079 Industrials 668 Consumer Cyclical 490 Basic Materials 337 Consumer Defensive 248 Communication Services 213 Utilities 183 Energy 165 Real Estate 80

1,116 stocks · page 1 of 19

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.

AGILENT TECHNOLOGIES, INC.

Deeply overvalued

Premium +147% Return to IV: -59.4%

Owner yield 2.7% 10-yr IRR -0.6% · steady

Market implies +16.0%/yr vs model +4.7% · above model

ASCENTAGE PHARMA GROUP INTERNATIONAL

Aardvark Therapeutics, Inc.

Model IV$208.02

Premium +27% Return to IV: -21.2%

Owner yield 3.9% 10-yr IRR 3.8% · steady

Market implies +7.0%/yr vs model +4.5% · in line

AbCellera Biologics Inc.

Market implies +111.1%/yr vs model +2.0% · above model

ABEONA THERAPEUTICS INC.

Market implies +52.7%/yr vs model +18.0% · above model

Acumen Pharmaceuticals, Inc.

ABBOTT LABORATORIES

Model IV$104.52

Discount 2% Return to IV: +1.9%

Owner yield 3.5% 10-yr IRR 2.0% · steady

Market implies +3.3%/yr vs model +4.1% · in line

Arbutus Biopharma Corp

Market implies +84.2%/yr vs model +2.0% · above model

ABVC BIOPHARMA, INC.

Market implies +64.2%/yr vs model +2.0% · above model

ACADIA PHARMACEUTICALS INC

Deeply overvalued

Premium +164% Return to IV: -62.1%

Market implies +27.4%/yr vs model +18.4% · above model

AURORA CANNABIS INC

Adicet Bio, Inc.

Acadia Healthcare Company, Inc.

Deeply undervalued

Discount 34% Return to IV: +52.5%

Market implies +1.0%/yr vs model +8.0% · below model

ACHIEVE LIFE SCIENCES, INC.

Alpha Cognition Inc.

Market implies +29.9%/yr vs model +15.0% · above model

Market implies +31.6%/yr vs model +5.9% · above model

Deeply undervalued

Discount 57% Return to IV: +134.4%

Market implies -25.0%/yr vs model +5.9% · below model

Aclaris Therapeutics, Inc.

Market implies +36.5%/yr vs model +3.7% · above model

Acrivon Therapeutics, Inc.

ACTUATE THERAPEUTICS, INC.

Acurx Pharmaceuticals, Inc.

Market implies +44.7%/yr vs model +2.0% · above model

ADC Therapeutics SA

Market implies +11.1%/yr vs model +15.0% · below model

Adagio Medical Holdings, Inc.

Market implies +40.3%/yr vs model +15.0% · above model

ADIAL PHARMACEUTICALS, INC.

ADMA BIOLOGICS, INC.

Deeply undervalued

Discount 48% Return to IV: +90.7%

Market implies -11.2%/yr vs model +50.0% · below model

Adaptive Biotechnologies Corp

Market implies +43.2%/yr vs model +15.7% · above model

Addus HomeCare Corp

Model IV$155.68

Discount 25% Return to IV: +33.0%

Owner yield 4.9% 10-yr IRR 12.6% · grower

Market implies +5.0%/yr vs model +12.3% · below model

Advanced Biomed Inc.

Addex Therapeutics Ltd.

AEHR TEST SYSTEMS

Market implies +58.4%/yr vs model +37.3% · above model

AETHLON MEDICAL INC

Market implies +34.0%/yr vs model +15.0% · above model

AEON Biopharma, Inc.

Market implies +50.1%/yr vs model +2.0% · above model

AGIOS PHARMACEUTICALS, INC.

Market implies +37.8%/yr vs model +15.0% · above model

agilon health, inc.

Deeply overvalued

Premium +117% Return to IV: -53.8%

Market implies +16.7%/yr vs model +40.5% · below model

Agomab Therapeutics NV

AdaptHealth Corp.

Deeply undervalued

Discount 85% Return to IV: +551.5%

Owner yield 25.9% 10-yr IRR 41.3% · moderate

Market implies -19.4%/yr vs model +8.1% · below model

AIM ImmunoTech Inc.

Market implies +12.5%/yr vs model +2.0% · above model

Airsculpt Technologies, Inc.

Deeply overvalued

Premium +31% Return to IV: -23.9%

Market implies +8.6%/yr vs model +3.3% · above model

Akebia Therapeutics, Inc.

Deeply overvalued

Premium +43% Return to IV: -30.1%

Market implies +3.5%/yr vs model +2.0% · in line

Aktis Oncology, Inc.

Akari Therapeutics Plc

Deeply undervalued

Model IV$213.61

Discount 70% Return to IV: +228.4%

Owner yield 6.2% 10-yr IRR 18.2% · grower

Market implies +1.1%/yr vs model +21.9% · below model

Aldeyra Therapeutics, Inc.

Market implies +80.3%/yr vs model +2.0% · above model

ALIGN TECHNOLOGY INC

Deeply overvalued

Premium +169% Return to IV: -62.8%

Owner yield 5.4% 10-yr IRR 8.8% · steady

Market implies +19.0%/yr vs model +5.7% · above model

Aligos Therapeutics, Inc.

Market implies +50.7%/yr vs model +15.0% · above model

Discount 4% Return to IV: +4.1%

Owner yield 5.6% 10-yr IRR 10.6% · moderate

Market implies +5.3%/yr vs model +7.1% · in line

Allogene Therapeutics, Inc.

Market implies +150.0%/yr vs model +15.0% · above model

Allarity Therapeutics, Inc.

Market implies +64.3%/yr vs model +15.0% · above model

Alamar Biosciences, Inc.

Market implies +46.9%/yr vs model +15.0% · above model

Deeply overvalued

Premium +202% Return to IV: -66.8%

Owner yield 2.3% 10-yr IRR 0.3% · moderate

Market implies +22.4%/yr vs model +8.8% · above model

ALNYLAM PHARMACEUTICALS, INC.

Deeply undervalued

Model IV$347.64

Discount 31% Return to IV: +45.1%

Market implies -10.5%/yr vs model +44.8% · below model